Search

Displaying results 2691 - 2700 of 4590 in total
  1. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … _ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by

  2. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with … The vaccine is created by weakening the wildtype before being placed into the oral vaccine.

  3. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  4. Drug

    Manganese gluconate

    go.drugbank.com/drugs/DB11141
    Approved

    It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.

  5. Drug

    Chromium picolinate

    go.drugbank.com/drugs/DB11255
    Approved

    Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor [A27235].

  6. Drug

    Etifoxine

    go.drugbank.com/drugs/DB08986
    ApprovedWithdrawn

    Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing.

  7. Drug

    Fluorescein

    go.drugbank.com/drugs/DB00693
    ApprovedInvestigational

    It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)

  8. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions. … In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation of COVID-19 Therapy (RECOVERY), it was reported that dexamethasone reduced COVID-19 deaths by approximately

  9. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits

  10. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic